3 results
To evaluate the proportion of patients indicating an overall preference via a Patient Preference Questionnaire (PPQ) for either the subcutaneous (SC) or the intravenous (IV) route of rituximab administration.
The primary objective of the study is to compare the efficacy of brigatinib to that of crizotinib in ALK+ locally advanced or metastatic NSCLC patients naive to ALK inhibitors, as evidenced by PFS.The secondary objectives of the study are:1. To…
Main study: to examine whether low dose GC therapy is more effective via the oral route compared to the parenteral route.Dose finding study (pilot study): to examine which oral GC dose is needed for a noticeable decrease in Erythrocyte Sedimentation…